PT3892302T - Composições que contêm ibrutinib - Google Patents

Composições que contêm ibrutinib

Info

Publication number
PT3892302T
PT3892302T PT211618285T PT21161828T PT3892302T PT 3892302 T PT3892302 T PT 3892302T PT 211618285 T PT211618285 T PT 211618285T PT 21161828 T PT21161828 T PT 21161828T PT 3892302 T PT3892302 T PT 3892302T
Authority
PT
Portugal
Prior art keywords
compositions containing
containing ibrutinib
ibrutinib
compositions
Prior art date
Application number
PT211618285T
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3892302(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT3892302T publication Critical patent/PT3892302T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/22—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT211618285T 2015-04-06 2016-04-06 Composições que contêm ibrutinib PT3892302T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06

Publications (1)

Publication Number Publication Date
PT3892302T true PT3892302T (pt) 2023-11-15

Family

ID=55806788

Family Applications (1)

Application Number Title Priority Date Filing Date
PT211618285T PT3892302T (pt) 2015-04-06 2016-04-06 Composições que contêm ibrutinib

Country Status (28)

Country Link
US (5) US20160287594A1 (pt)
EP (3) EP3280446A1 (pt)
JP (3) JP2018513852A (pt)
KR (2) KR102632745B1 (pt)
CN (2) CN107530293A (pt)
AU (3) AU2016246669B2 (pt)
CA (1) CA2981601A1 (pt)
CL (1) CL2017002512A1 (pt)
DK (1) DK3892302T3 (pt)
EA (1) EA033992B1 (pt)
ES (1) ES2964472T3 (pt)
FI (1) FI3892302T3 (pt)
HK (1) HK1250925A1 (pt)
HR (1) HRP20231207T1 (pt)
HU (1) HUE063751T2 (pt)
IL (2) IL295941A (pt)
LT (1) LT3892302T (pt)
MA (2) MA54411B1 (pt)
MD (1) MD3892302T2 (pt)
MX (2) MX2017012822A (pt)
PH (1) PH12017501811A1 (pt)
PL (1) PL3892302T3 (pt)
PT (1) PT3892302T (pt)
RS (1) RS64653B1 (pt)
SG (2) SG10202103458QA (pt)
SI (1) SI3892302T1 (pt)
UA (1) UA125681C2 (pt)
WO (1) WO2016164404A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200017549A (ko) 2012-06-04 2020-02-18 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
KR20170033358A (ko) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
BR112017018931A2 (pt) 2015-03-03 2018-07-31 Pharmacyclics Llc formulações farmacêuticas de um inibidor de tirosina quinase de bruton
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PREPARATION METHOD THEREOF
EA202090573A1 (ru) 2017-09-26 2020-09-07 Тесаро, Инк. Составы нирапариба
WO2019142207A1 (en) * 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
KR20190122561A (ko) * 2018-04-21 2019-10-30 류형준 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
MX2020013684A (es) 2018-06-15 2021-03-02 Janssen Pharmaceutica Nv Formulaciones/composiciones que comprenden ibrutinib.
US20210308044A1 (en) * 2018-08-18 2021-10-07 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
US20230255885A1 (en) * 2018-08-18 2023-08-17 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
KR102198502B1 (ko) * 2018-09-16 2021-01-05 류형준 인체의 림프순환 개선을 위한 식품 조성물
CN113164782A (zh) * 2018-11-30 2021-07-23 詹森生物科技公司 治疗滤泡型淋巴瘤的方法
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
KR102251435B1 (ko) * 2020-11-09 2021-05-11 류형준 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
WO2022260667A1 (en) * 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Oral dosage forms of ibrutinib

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006013114D1 (de) * 2005-04-28 2010-05-06 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
EP2526933B1 (en) 2006-09-22 2015-02-25 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
WO2011153514A2 (en) 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
MX361772B (es) * 2011-10-19 2018-12-17 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
KR20200017549A (ko) * 2012-06-04 2020-02-18 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
US20150140085A1 (en) * 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
EP3603715B1 (en) 2013-03-14 2021-03-03 Fisher & Paykel Healthcare Limited Catheter mount with suction port
CA2920821A1 (en) * 2013-08-12 2015-02-19 The Yokohama Rubber Co., Ltd. Primer composition
CA2920534A1 (en) * 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
WO2015071432A1 (en) 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
KR20170033358A (ko) * 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
BR112017018931A2 (pt) * 2015-03-03 2018-07-31 Pharmacyclics Llc formulações farmacêuticas de um inibidor de tirosina quinase de bruton

Also Published As

Publication number Publication date
AU2016246669A1 (en) 2017-10-12
AU2024200883A1 (en) 2024-02-29
FI3892302T3 (fi) 2023-11-03
US20160287594A1 (en) 2016-10-06
CN107530293A (zh) 2018-01-02
JP7438178B2 (ja) 2024-02-26
EP3280446A1 (en) 2018-02-14
ES2964472T3 (es) 2024-04-08
SG11201707989PA (en) 2017-10-30
SG10202103458QA (en) 2021-05-28
AU2021250925B2 (en) 2023-11-16
US20170252344A1 (en) 2017-09-07
MA41901A (fr) 2021-04-14
IL295941A (en) 2022-10-01
PH12017501811A1 (en) 2018-04-23
EP3892302B1 (en) 2023-09-06
RS64653B1 (sr) 2023-10-31
US20230263804A1 (en) 2023-08-24
EP4272835A2 (en) 2023-11-08
EP4272835A3 (en) 2023-12-20
CN113546054A (zh) 2021-10-26
MA54411B1 (fr) 2023-11-30
MA54411A (fr) 2021-10-13
MX2017012822A (es) 2018-06-13
MD3892302T2 (ro) 2024-03-31
IL254695B (en) 2022-10-01
CA2981601A1 (en) 2016-10-13
US20220211713A1 (en) 2022-07-07
US20200171036A1 (en) 2020-06-04
CL2017002512A1 (es) 2018-03-16
KR102632745B1 (ko) 2024-02-01
HRP20231207T1 (hr) 2024-01-19
EA201792224A1 (ru) 2018-06-29
JP2024026087A (ja) 2024-02-28
MX2021015250A (es) 2022-01-24
UA125681C2 (uk) 2022-05-18
LT3892302T (lt) 2023-11-10
HK1250925A1 (zh) 2019-01-18
JP2022031690A (ja) 2022-02-22
PL3892302T3 (pl) 2024-03-11
KR20170134582A (ko) 2017-12-06
IL254695A0 (en) 2017-11-30
HUE063751T2 (hu) 2024-01-28
IL254695B2 (en) 2023-02-01
AU2016246669B2 (en) 2021-07-15
WO2016164404A1 (en) 2016-10-13
EP3892302A1 (en) 2021-10-13
JP2018513852A (ja) 2018-05-31
SI3892302T1 (sl) 2023-11-30
KR20240013859A (ko) 2024-01-30
DK3892302T3 (da) 2023-11-13
EA033992B1 (ru) 2019-12-17
AU2021250925A1 (en) 2021-11-11
EP3892302B8 (en) 2023-10-18
BR112017021325A2 (pt) 2018-06-26

Similar Documents

Publication Publication Date Title
HK1250925A1 (zh) 包含依魯替尼的組合物
GB201512030D0 (en) Composition
GB201601572D0 (en) NO containing compositions
GB201505527D0 (en) Composition
GB201506827D0 (en) Composition
GB201515640D0 (en) Composition
GB201506830D0 (en) Composition
GB201506829D0 (en) Composition
GB201506825D0 (en) Composition
GB201517546D0 (en) Composition
GB201506828D0 (en) Composition
GB201518348D0 (en) Composition
GB201514585D0 (en) Composition
GB201511697D0 (en) Composition
GB201509044D0 (en) Composition
GB201505520D0 (en) Composition
GB201504665D0 (en) Composition
GB201504307D0 (en) Composition
GB2536640B (en) Epilatory compositions
GB201515639D0 (en) Composition
GB201508722D0 (en) Composition
GB201506826D0 (en) Composition
GB2536642B (en) Epilatory compositions
GB201519054D0 (en) Composition
GB201515734D0 (en) Composition